Physician profile
Anna Kogan
NPI 1326208166
$3,141.99
in general payments reported to CMS, 2019-2025
25 companies · $597 in 2025
The $597 reported for 2025 was more than what a typical Neuromuscular Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $530).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $27.94 · 2021: $230 · 2022: $603 · 2023: $531 · 2024: $1,013 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,140.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $763.24 | 2021-2025 | Valtoco |
| Ucb, INC. | $618.22 | 2021-2025 | Briviact |
| Otsuka America Pharmaceutical, INC. | $314.58 | 2023-2025 | Rexulti |
| Abbvie INC. | $290.81 | 2021-2024 | |
| Lundbeck LLC | $155.40 | 2024-2025 | Vyepti |
| Amgen INC. | $140.31 | 2019 | |
| Eisai INC. | $135.54 | 2021-2025 | |
| Abbott Laboratories | $102.26 | 2023 | Infinity |
| Lilly USA, LLC | $80.18 | 2021-2024 | Amyvid, Emgality |
| Pfizer INC. | $75.02 | 2023-2025 | |
| Sk Life Science, INC. | $71.46 | 2024-2025 | |
| Nevro Corp. | $49.46 | 2022 | |
| Allergan, INC. | $42.96 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $36.88 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.08 | 2025 | Trintellix |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $29.01 | 2024 | Ocrevus |
| Axsome Therapeutics, INC. | $27.86 | 2025 | Symbravo |
| Springworks Therapeutics, INC. | $27.77 | 2025 | Gomekli |
| Averitas Pharma INC. | $27.20 | 2025 | Qutenza |
| Neurocrine Biosciences, INC. | $26.61 | 2022 | |
| Vanda Pharmaceuticals INC. | $24.31 | 2025 | Ponvory |
| Biogen, INC. | $22.45 | 2023 | Spinraza |
| Azurity Pharmaceuticals, INC. | $18.76 | 2024 | Horizant |
| Cumberland Pharmaceuticals, INC. | $14.71 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $13.91 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Kogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.